Managing diabetic dyslipidemia: Aggressive approach

Journal of the American Osteopathic Association

Volumn 109, Issue 5 SUPPL. 1, 2009, Pages

  Spratt, Kelly Anne ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PENN PRESBYTERIAN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID SEQUESTRANT; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DIET; DISEASE ASSOCIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EXERCISE; HUMAN; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; UNITED STATES;

AGED; BODY MASS INDEX; COMBINED MODALITY THERAPY; COMORBIDITY; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; EXERCISE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE STYLE; MALE; MIDDLE AGED; OBESITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 66749130805     PISSN: 00986151     EISSN: 00986151     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25:1129-1134. (Pubitemid 41071162)
2. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from CHD in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234. Available at http://content.nejm.org/cgi/content/abstract/339/4/229. Accessed March 1, 2009.
3. Jacobs MJ, Kielsil T, Pio JR, Malik S, L'Italien GJ, Chen RS, Wong ND. Prevalance and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract. 2005;70:263-269. (Pubitemid 41539788)
4. Mora S, Szklo M, Otvos JD, Greenland P, Psaty BM, Goff DC Jr, et al. LDL particle subclasses, LDL particle size and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2007;192:211-217. (Pubitemid 46602300)
5. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, et al. Effect of insulin resistance and Type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003;52:453-462. Available at: http://diabetesjournals.org/cgi/ content/full/52/2/453. Accessed May 7, 2009. (Pubitemid 36173203)
6. Vakkilainen J, Steiner G, Anaquer J-C, Aubin F, Rattier S, Foucher C, et al. Relationship between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS) [published online ahead of print March 4, 2003]. Circulation. 2003;107:1733-1737. Available at http://circahajournals. org/cgi/content/full/107/13/1733. Accessed February 20, 2009. (Pubitemid 36418352)
7. St-Pierre A, Cantin B, Dagenais GR, Mayrièe P, Bernard P-M, Després J-P, et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study [published online ahead of print December 23, 2004]. Arterioscler Thromb Vasc Biol. 2005;25:553-559. Available at: http://atvb.ahajournals.org/cgi/content/full/25/3/553. Accessed March 1, 2009. (Pubitemid 40315677)
8. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease - The Framingham Heart Study.Can J Cardiol.1998;4(suppl A):5A-10A.
9. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. Bethesda, Md: National Cholesterol Education Program. National Heart, Lung, and Blood Institute, National Institutes of Health. NIH Publication No. 02-5215, September 2002.
10. Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials [published online ahead of print April 3, 2006]. BMJ. 2006;332:1115-1124.
11. Fontbonne A, Eschwè E, Cambien E, Richard JL, Ducimetière P, Thibult N, et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year followup of the Paris Prospective Study. Diabetologia. 1989;32:300-304. (Pubitemid 19166483)
12. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-219. (Pubitemid 26266496)
13. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation. 2007;15:450-458. Available at: http://circ.ahajournals .org/cgi /content/full/115/4/450. Accessed April 14, 2009. (Pubitemid 46184196)
14. Ginsberg HN. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation. 2002;106:2137-2142. Available at: http://circ.ahajournals.org/cgi/reprint/106/16/2137. Accessed April 14, 2009. (Pubitemid 35192822)
15. Haskell WL, Lee I-M, Pate rr, Powell KE, Blair SN, Franklin BA, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation. 2007;116:1081-1093. (Pubitemid 47329572)
16. Kontush A, Chapman MJ. Antiatherogenic small dense HDL: guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med. 2006;3:144-153. (Pubitemid 43307515)
17. Haskell WL, Lee I-M, Pate RR, Powell KE, Blair SN, Franklin BA, et al; american College of Sports Medicine, American Heart Association. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association [published online ahead of print August 1, 2007]. Circulation. 2007;116:1081-1093. Available at: http://circ.ahajournals.org/cgi/reprint/116/9/1081. Accessed April 14, 2009.
18. GISSI Prevenzione Investigators (Gruppo Italiano per to Studio della Sopravvivenza nell'Infarto miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999;354:447-455. (Pubitemid 29368922)
19. Berthold HK, Unverdorben S, Degenhardt R, Bulitta M, Gouni-Berthold I. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: A randomized controlled trial. JAMA. 2006;295:2262-2269. Available at: http://jama.ama-assn.org/cgi /content/full/295/19/2262. Accessed April 14, 2009. (Pubitemid 43736576)
20. Gardner CD, Lawson LD, Block, Chatterjee LM, Kiazand A, Balise RR, et al. Effect of raw garlic or garlic supplements on plasma lipid concentrations in adults with hypercholesterolemia: a randomized clinical trial. Arch Intern Med. 2007;167:346-353. Available at: http://archinte.ama-assn.org/cgi /content/full/167/4/346. Accessed April 14, 2009. (Pubitemid 46333934)
21. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study(4S). Lancet. 1994;344:1383-1389. (Pubitemid 24365311)
22. Sherpherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al; for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307. Available at: http://content.nejm.org/cgi/content/ abstract/333/20/1301. Accessed April 14, 2009.
23. Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCaps). Circulation. 2000;101:477-484. Available at: http://circ.ahajournals.org/cgi /content/full/101/5/477. Accessed April 14, 2009. (Pubitemid 30080860)
24. Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med. 2004;140:650-658. (Pubitemid 38500451)
25. Becker DJ, Gordon RY, Morris PB, Yorko J, Gordon YJ, Li M, et al. Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. Mayo Clin Proc. 2008;83:758-764. Available at: http://www.mayoclinic proceedings.com/content/83/7/758.long. Accessed April 14, 2009.
26. Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, et al; Chinese Coronary Secondary Prevention Study Group, Li S. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction [published online ahead of print April 11, 2008]. Am J Cardiol. 2008;101:1689-1690.
27. Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme q10 on myopathic symptoms in patients treated with statin medications [published online ahead of print April 3, 2007]. Am J Cardiol. 2007;9:1497-1498.
28. Tenkanen L, Mäntiäri M, Kovanen PT, Virkkunen HM, Manninen V. Gemfibrozil in the treatment of dyslipidemia. An 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med. 2006;166: 743-748. Available at: http://archinte.amaassn.org /cgi/reprint/166/7/743. Accessed March 4, 2009.
29. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, et al; VA-HIT Study Group. Veterans Affairs High-Density Liporotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events. JAMA. 2007;285:1585-1591. Available at: http://jama.ama-assn.org/cgi/content/full/285/12/1585. Accessed April 14, 2009.
30. Keech A. Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial [published corrections appear in Lancet. 2006;368:1415; 2006;368:1420]. Lancet. 2005;366: 1849-1861.
31. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol. 2005;5:462-468. (Pubitemid 40247539)
32. Ginsberg HN, Bonds DE, Lovato LC, Crouse JR, Elam MB, Linz PE, et al; ACCORD Study Group. Evolution of the lipid portion of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99:56-67. (Pubitemid 46961886)
33. May HT, Anderson JL, Pearson RR, Jensen JR, Horne BD, Lavasani F, et al. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plous fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study [published online ahead of print December 26, 2007]. Am J Cardiol. 2008;101:486-489.
34. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592. Available at: http://content.nejm.org/cgi/content/abstract/345/22/1583. Accessed April 14, 2009. (Pubitemid 33126837)
35. Zhao XQ, Morse JS, Dowdy AA, Heise N, DeAngelis D, Frohlich J, et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol. 2004;93:307-312. (Pubitemid 38167426)
36. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al; ENHANCE Investigaators. Simvastatin with or without ezetimibe in familial hypercholesterolemia [published online ahead of print March 30, 2008]. N Engl J Med. 2008;358:1431-1443. Available at: http://content.nejm.org/cgi/content/ abstract/358/14/1431. Accessed April 14, 2009.
37. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis [published online ahead of print September 2, 2008]. N Engl J Med. 2008;359:1343-1356. Available at: http://content.nejm.org/ cgi/content/abstract/359/13/1343. Accessed April 14, 2008.
38. Peto R, Emberson J, Landray M, Baigent C, Collins R, Clare R, et al. Analysis of cancer data from three ezetimibe trials [published online ahead of print September 2, 2008]. N Engl J Med. 2008;359:1357-1366. Available at: http://content.nejm.org/cgi/content/abstract/359/13/1357. Accessed April 2009.
39. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl . May 2003 (84):S207-S216. (Pubitemid 36513411)
40. Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, et al; IMPROVEIT Investigators. Rational and design of IMPROVEIT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/ simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with coronary syndromes [published online ahead of print September 2, 2008]. Am Heart J. 2008;156:826-832.
41. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al; Cholesterol Treatment Trialists' (CTT) collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [published online ahead of print September 27, 2005] [published corrections appear in Lancet. 2005;366:1358, 2008;371:2084]. Lancet. 2005;366:1267-1278.